June 2018- Volume 14, Issue 6

In this Issue

Diagnostics

Expanding the value for Oncomine Dx

Expanding the value for Oncomine Dx

A pair of new deals with Daiichi and Takeda help move Thermo’s technology forward

Exosomes to the rescue?

Exosomes to the rescue?

Minimally invasive test provides early breast cancer detection

G6PD deficiency diagnosis

G6PD deficiency diagnosis

PATH, Mologic work to identify malaria patients at risk of side effects from standard malaria treatment

Amarantus lines up future efforts for LymPro

Amarantus lines up future efforts for LymPro

The company is pursuing a license agreement with Leipzig University, as well as a second clinical study

Contract Services

Recipharm teams up with Hadasit

Recipharm teams up with Hadasit

Partnership created with the goal of delivering seamless chemical and clinical services

Rounding the oncology bases

Rounding the oncology bases

CrownBio launches new humanized model, enters strategic partnership with Phanes and presents many posters at AACR 2018

NanoString partners with CROs on DSP service

NanoString partners with CROs on DSP service

Expanded technology access program is a response to interest from leading biopharma companies and lab service providers

Clinical Trials

Future looking bright for eClinical solutions

Future looking bright for eClinical solutions

Market to cross $4-billion mark by 2020, driven by unified cloud-based platforms with scalability and modularity

Phase 1 phenomenon

Phase 1 phenomenon

First-in-class EZH2 inhibitor demonstrates safety and efficacy

In pursuit of HIV

In pursuit of HIV

Inovio Pennvax-GP HIV vaccine sustained durable memory responses measured one year after the start of the clinical trial

Potential game-changer for OA

Potential game-changer for OA

Flexion Therapeutics explores current and future opportunities for Zilretta, a non-opioid injection for pain

Discovery

XtalPi and Pfizer collaborate on AI

XtalPi and Pfizer collaborate on AI

Aim is to develop artificial intelligence-powered molecular modeling tech for drug discovery

An AI approach to malaria

An AI approach to malaria

Gates Foundation grant to fund work by Recursion and UC San Diego in malaria treatment discovery

It’s molecular!

It’s molecular!

Fujitsu develops molecular simulation technology to effectively create new drug candidates

The next dimension in drug testing

The next dimension in drug testing

Scripps scientists use 3D spheroids to better test cancer drugs’ efficacy

Preclinical

Injectable nanos vs. tumors

Injectable nanos vs. tumors

Nanobiotix and Weill Cornell Medicine enter research collaboration

‘Building a better ADC’

‘Building a better ADC’

Sutro Biopharma advances STRO-001 and STRO-002 into the clinic against multiple cancer types

Relief for devastating skin disease?

Relief for devastating skin disease?

Human placental-derived stem cells boost survival, collagen deposition in mouse models of RDEB

New data on ALG.APV-527 for solid tumors

New data on ALG.APV-527 for solid tumors

Aptevo and Alligator present preclinical data for novel immunotherapy bispecific candidate

Episodic memory replay

Episodic memory replay

Rats’ replay of events has implications for AD treatments

Research & Development

Triboluminescence at Purdue

Triboluminescence at Purdue

Researchers create triboluminescence instrument to rapidly test whether drugs contain trace crystallinity

Rosalind Franklin has another growth spurt

Rosalind Franklin has another growth spurt

University announces three new disease-based scientific additions to its research park

Illumina ‘tames’ a DRAGEN

Illumina ‘tames’ a DRAGEN

Company gains Edico’s DRAGEN Bio-IT tech for next-generation sequencing in acquisition

Dopamine receptors as cancer biomarker

Dopamine receptors as cancer biomarker

HKBU develops iridium probes that could lead to novel early-detection technology for cancer

Business & Government Policy

Beam launches into base editing

Beam launches into base editing

New company plans to build on CRISPR tech to enable single-letter editing of DNA and RNA

Celsius launches with $65M in financing

Celsius launches with $65M in financing

Company seeks to develop precision therapeutics for people with autoimmune diseases and cancer

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Fate and MSK expand oncology license deal

Fate and MSK expand oncology license deal

Updated agreement to include gene-edited T cell immunotherapies

An agreement at last

An agreement at last

Shire commits to Takeda’s latest acquisition offer of roughly $62 billion

Special Reports

Editor's Focus

Editor’s focus: Medicines going digital?

Editor’s focus: Medicines going digital?

Before we start getting too comfortable using terms like "digital therapeutics" or "digiceuticals" maybe we should establish exactly what they are

Commentary

Guest commentary: Improving clinical trial design in acute pain

Guest commentary: Improving clinical trial design in acute pain

Biopharma companies must consider a great deal when designing a trial that will enable a pain medication to show significant treatment effect compared to placebo

Rats and me

Rats and me

There remains a place for animal testing with regard to human therapeutics, even as the space grows to use non-animal alternatives more

Feature

Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 9 • September 2021

September 2021

September 2021 Issue